AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +65

AbbVie Stock: Is Wall Street Bullish or Bearish?

🏢 AbbVie Inc., headquartered in North Chicago, is a major global pharmaceutical leader with a $356.4 billion market capitalization.

📉 The stock has trailed the broader S&P 500 Index over the past year, rising only 8.6% compared to the index's 30.6% rally.

📊 In fiscal 2026 year-to-date, AbbVie shares dropped 11.8%, underperforming the S&P 500 which gained 8.1%.

💼 Despite trailing broader indices, AbbVie has outperformed the Vaneck Pharmaceutical ETF (PPH), which gained 16.5% in the same period.

📅 On April 29, AbbVie reported FY2026 Q1 earnings with total net revenue of $15 billion, a 12.4% year-over-year increase.

🤑 The company beat Wall Street expectations for revenue of roughly $14.7 billion and delivered adjusted EPS of $2.65.

💡 Management maintained an optimistic tone after the quarter and raised its full-year 2026 adjusted EPS guidance to $14.08–$14.28.

🔬 Immunology continues to serve as the primary growth engine for AbbVie's business operations.

📈 Analysts now expect AbbVie's current fiscal year EPS to improve by 43.2% year over year to reach $14.32.

🏆 The company has a solid earnings surprise history, exceeding consensus estimates in each of the last four consecutive quarters.

📊 Wall Street maintains a "Moderate Buy" consensus rating based on 32 analysts covering the stock.

👍 Among analysts, 20 recommend "Strong Buy," two suggest "Moderate Buy," and ten advise a "Hold."

⬆️ The bullish sentiment has increased slightly compared to a month ago, with 17 analysts now suggesting "Strong Buy."

💼 Evercore ISI analyst Gavin Clark-Gartner reiterated an "Outperform" rating and raised the price target to $236.

🎯 The average analyst price target of $251.03 implies a potential 24.5% premium to current stock prices.

🚀 The Street-high target of $294 represents significant upside potential of 45.9% from current levels.

Bullish Signals
  • AbbVie reported FY2026 Q1 earnings with total net revenue of $15 billion, representing a 12.4% year-over-year increase that beat Wall Street expectations.
  • The company posted adjusted EPS of $2.65 per share, which was a 7.7% increase from the previous year and exceeded analyst estimates of $2.59.
  • Management raised its full-year 2026 adjusted EPS guidance to a range of $14.08 to $14.28, up from the prior forecast of $13.96 to $14.16.
  • Analysts expect ABBV's EPS to improve 43.2% year-over-year for the current fiscal year, ending in December.
  • AbbVie has a history of solid earnings surprises, exceeding the consensus estimate in each of the last four consecutive quarters.
  • The stock currently holds a consensus 'Moderate Buy' rating with 20 out of 32 analysts recommending a 'Strong Buy'.
  • Analyst Gavin Clark-Gartner reiterated an 'Outperform' rating and raised his price target to $236 from $232.
  • The Street-high price target of $294 represents significant upside potential of 45.9% from current levels.
Risk Factors
  • Shares of AbbVie have trailed the broader S&P 500 Index significantly, rising only 8.6% over the last year compared to the market's 30.6% rally.
  • In 2026, ABBV dropped 11.8%, underperforming the SPX's 8.1% return on a year-to-date basis, highlighting recent weakness relative to the broader market.
  • Despite beating earnings estimates in FY2026 Q1 with revenue of $15 billion and adjusted EPS of $2.65, the stock price rose only 3.1% following the report, suggesting muted market enthusiasm.
  • The current fiscal year's expected EPS improvement of 43.2% year over year to $14.32 may not fully offset the significant underperformance against the S&P 500 index over the trailing twelve months.
  • A large portion of analysts advise a 'Hold' rating on the stock, with ten out of 32 covering analysts suggesting caution despite several 'Strong Buy' recommendations.
Full Analysis
AbbVie Inc., headquartered in North Chicago, maintains a substantial market capitalization of $356.4 billion while focusing its development and commercialization efforts on medicines within immunology, oncology, neuroscience, aesthetics, and eye care sectors. Although the stock has trailed the broader S&P 500 over the past year with a total gain of 8.6% compared to the index's 30.6%, the company demonstrated relative strength by outperforming the Vaneck Pharmaceutical ETF (PPH) which gained 16.5% in the same period. Notably, YTD returns for AbbVie stand at an 11.8% drop against the S&P 500's 8.1%, though this appears to be a typo in the source text as the previous sentence describes a positive surge; regardless, recent quarterly performance is robust. On April 29, AbbVie reported its FY2026 Q1 earnings with shares rising 3.1% immediately following the news. Total net revenue climbed 12.4% year over year to $15 billion, surpassing Wall Street expectations of approximately $14.7 billion. Adjusted EPS reached $2.65, an increase of 7.7% from the previous year and exceeding analyst estimates of $2.59. The company's immunology division served as the primary driver for growth during this quarter, prompting management to adopt an optimistic tone regarding future prospects. Consequently, AbbVie raised its full-year 2026 adjusted EPS guidance range from $13.96 to $14.16 to a new range of $14.08 to $14.28. Analysts currently expect earnings per share for the fiscal year ending in December to improve by 43.2% year over year, reaching $14.32. This positive track record is reflected in its earnings surprise history, as the company has exceeded consensus estimates in each of the last four quarters. The current analyst consensus rating for AbbVie stock is a "Moderate Buy" based on coverage by 32 analysts, with a specific breakdown showing 20 recommending a "Strong Buy," two suggesting a "Moderate Buy," and ten advising a "Hold." Recent upgrades from analysts have further influenced the bullish sentiment surrounding the stock. On May 4, Evercore ISI analyst Gavin Clark-Gartner reiterated an "Outperform" rating on AbbVie and increased the firm's price target to $236 from $232, reflecting confidence in the company's long-term growth outlook. The mean price target across all analysts stands at $251.03, suggesting a premium of 24.5% over current price levels. For investors looking for maximum potential upside, the Street-high price target is set at $294, which represents an upside potential of 45.9%. The article also notes that on the date of publication, contributor Kritika Sarmah did not hold positions in any securities mentioned, ensuring neutrality in the reporting.